Kineta, Inc. is a clinical-stage biotechnology company with a focus on developing immunotherapies that transform patients' lives.

It focuses on developing potentially differentiated immunotherapies that address the challenges with current cancer therapy.

The company's immuno-oncology pipeline includes KVA12123, a VISTA blocking immunotherapy in development as a twice weekly monoclonal antibody (mAb) infusion drug.

KVA12123 is being evaluated in a Phase 1/2 clinical trial as a monotherapy and in combination with pembrolizumab in patients with advanced solid tumors, including non-small cell lung, ovarian, head and neck, renal cell, and colorectal cancers.

It is also developing anti-CD27 agonist mAb immunotherapy, which is in preclinical development for advanced solid tumors, such as renal cell carcinoma, ovarian, and colorectal cancers.

The company has collaboration and license agreements with MSD International Business GmbH, Genentech, Inc., FAIR Therapeutics B.V., and GigaGen, Inc. Kineta, Inc. was founded in 2007 and is headquartered in Seattle, Washington.